This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Cardiovascular Disease and Vascular Surgery



December 2017

Rivaroxaban (Xarelto) in Combination with Aspirin for Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease

Rivaroxaban and aspirin are drugs that reduce blood clots in blood vessels and are currently being given to some patients with CAD and PAD. The combination of rivaroxaban with aspirin is being developed as a more effective treatment.


September 2017

Canakinumab (ILARIS®) for Cardiovascular risk reduction – Add on therapy

Cardiovascular disease (CVD) is a general term that refers to all conditions affecting the heart and blood vessels (circulation). These include angina, heart attack (also known as myocardial infarction), heart failure, stroke, and a number of diseases that affect the blood vessels. CVD is usually associated with a build-up of fatty deposits inside the blood …


March 2017

Magnetically-Enhanced Diffusion System for acute ischaemic stroke

The Magnetically-Enhanced Diffusion (MED) System™ in development by Pulse Therapeutics, Inc is designed to improve the delivery of thrombolytic therapy in people who have had an acute ischaemic stroke by using intravenously-injected iron nanoparticles and an externally positioned rotating magnetic field.


February 2017

Anacetrapib in combination with a statin for patients with primary hypercholesterolaemia or mixed dyslipidaemia – adjunctive therapy

Anacetrapib is a new drug that may reduce the level of fats, like cholesterol, in your blood. High cholesterol can increase the risk of diseases such as heart attack and stroke, which are the main cause of death in the UK, accounting for over a quarter of all deaths each year. Anacetrapib is given as …


November 2016

Evolocumab (Repatha) for cardiovascular event prevention – add on therapy

Evolocumab is a drug that may prevent cardiovascular events, such as heart attack or stroke, by reducing cholesterol. These diseases are the main cause of death in the UK, accounting for over a quarter of deaths each year. Evolocumab is given via an injection in combination with another drug (usually a statin) and changes to …


November 2016

Bococizumab for primary hyperlipidaemia and mixed dyslipidaemia – adjunctive to statin therapy and/or diet

Bococizumab is a new drug to treat high levels of fat and cholesterol in the bloodstream (primary hyperlipidemia and mixed dyslipidemia). These conditions can cause a build-up of fatty deposits (plaques) in the arteries, which may lead to heart attacks and strokes. Bococizumab is given by subcutaneous injection. Some studies have suggested that this drug …


October 2016

SMARTChip for early diagnosis of suspected stroke

SMARTChip is a point-of-care test to aid in the early diagnosis of stroke. It has been developed by Sarissa Biomedical Ltd. The test is intended for use in the emergency room and by paramedics on any patient satisfying the FAST (Face, Arms, Speech, Time) algorithm for suspected stroke. The assay uses a hand-held reader and …


August 2016

Ticagrelor (Brilique) for peripheral arterial disease

Peripheral arterial disease is a common condition in which a build-up of fatty deposit in the arteries (atherosclerosis) restricts blood supply to leg muscles. Many people with peripheral arterial disease have no symptoms. However, some people develop a painful ache in their legs when they walk, which usually disappears after a few minutes’ rest. While …


August 2016

Eleclazine for hypertrophic cardiomyopathy

Hypertrophic cardiomyopathy is a condition that causes the muscular wall of the heart to become thickened and stiff. The thickening makes it harder for the heart to pump blood around the body. Hypertrophic cardiomyopathy is a genetic condition that is caused by a change or fault (or mutation) in one or more genes. Eleclazine is …


July 2016

REVIEW – New and emerging angioplasty technologies for severe lower limb ischaemia

The NIHR Horizon Scanning Research and Intelligence Centre (HSRIC) conducted this horizon scanning scoping review on behalf of the Birmingham Clinical Trials Unit (BCTU) BASIL-3 clinical trial team. The aim of the review was to identify new and emerging angioplasty-related technologies for arterial revascularisation in patients with severe lower limb ischaemia due to femoro-popliteal artery …

Get Alerts